What Is Organon & Co. (OGN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Organon & Co.. Trading at $13.51 against an estimated intrinsic value of $27.92, 7 of 9 active models flag meaningful upside of +106.7% on average. The most optimistic model, Regime Cross, places fair value at $52.49 (+288.7%), while First Chicago — the most conservative — estimates $0.62 (-95.4%). This +384.1% gap reflects genuine analytical uncertainty about Organon & Co.'s intrinsic worth. Among models with highest confidence, Bayesian DCF lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About OGN?
9 of 13 models are currently active for OGN. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates OGN's intrinsic value at $46.39, implying +243.5% upside from the current price. See which stocks rank higher →
How Does OGN Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, OGN ranks #37 by Quality of Company score. CirclFi's QOC score of 7.9/10 evaluates 32 fundamental signals. A score of 7.9 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Organon & Co.'s positioning within the Pharmaceutical Preparations segment means that clinical trial success rate plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.
Is OGN a Value Trap?
CirclFi's Value Trap algorithm assigns OGN a score of 16/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Organon & Co.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Organon & Co. scores 7.9 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +384.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every OGN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across OGN's 9 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad